Literature DB >> 30676417

Neutrophil Extracellular Traps Are Elevated in Patients with Pneumonia-related Acute Respiratory Distress Syndrome.

Inès Bendib1, Luc de Chaisemartin, Vanessa Granger, Frédéric Schlemmer, Bernard Maitre, Sophie Hüe, Mathieu Surenaud, Asma Beldi-Ferchiou, Guillaume Carteaux, Keyvan Razazi, Sylvie Chollet-Martin, Armand Mekontso Dessap, Nicolas de Prost.   

Abstract

BACKGROUND: Neutrophil extracellular traps have been associated with tissue damage. Whether these are involved in the pathogenesis of human acute respiratory distress syndrome (ARDS) and could be a potential therapeutic target is unknown. The authors quantified bronchoalveolar and blood neutrophil extracellular traps in patients with pneumonia-related ARDS and assessed their relationship with ventilator-free days.
METHODS: Immunocompetent patients with pneumonia and moderate or severe ARDS (n = 35) and controls (n = 4) were included in a prospective monocentric study. Neutrophil extracellular trap concentrations were quantified (as DNA-myeloperoxidase complexes) in bronchoalveolar lavage fluid and serum by enzyme-linked immunosorbent assay. The relationship between bronchoalveolar lavage neutrophil extracellular trap concentrations and the primary clinical endpoint (i.e., the number of live ventilator-free days at day 28) was assessed using linear regression analyses.
RESULTS: There was no significant relationship between bronchoalveolar lavage neutrophil extracellular trap concentrations and ventilator-free days by multiple regression analysis (β coefficient = 2.40; 95% CI, -2.13 to 6.92; P = 0.288). Neutrophil extracellular trap concentrations were significantly higher in bronchoalveolar lavage than in blood of ARDS patients (median [first to third quartiles]:154 [74 to 1,000] vs. 26 [4 to 68] arbitrary units, difference: -94; 95% CI, -341 to -57; P < 0.0001). Bronchoalveolar concentrations of patients were higher than those of controls (154 [74 to 1,000] vs. 4 [4 to 4] arbitrary units, difference: -150; 95% CI, -996 to -64; P < 0.001) and associated with bronchoalveolar interleukin-8 (Spearman's ρ = 0.42; P = 0.012) and neutrophil concentrations (ρ = 0.57; P < 0.0001). Intensive care unit mortality (12%, n = 2 of 17 vs. 17%, n = 3 of 18; P > 0.99) and the number of ventilator-free days at day 28 (22 [14 to 25] vs. 14 [0 to 21] days; difference: -5; 95% CI, -15 to 0; P = 0.066) did not significantly differ between patients with higher (n = 17) versus lower (n = 18) bronchoalveolar neutrophil extracellular trap concentrations.
CONCLUSIONS: Bronchoalveolar neutrophil extracellular trap concentration was not significantly associated with mechanical ventilation duration in pneumonia-related ARDS.

Entities:  

Mesh:

Year:  2019        PMID: 30676417     DOI: 10.1097/ALN.0000000000002619

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  37 in total

1.  A Novel Assay for Neutrophil Extracellular Trap Formation Independently Predicts Disseminated Intravascular Coagulation and Mortality in Critically Ill Patients.

Authors:  Simon T Abrams; Ben Morton; Yasir Alhamdi; Mohmad Alsabani; Steven Lane; Ingeborg D Welters; Guozheng Wang; Cheng-Hock Toh
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

2.  Anti-Inflammatory Effects and Decreased Formation of Neutrophil Extracellular Traps by Enoxaparin in COVID-19 Patients.

Authors:  Supichcha Saithong; Wilasinee Saisorn; Punyot Tovichayathamrong; Grace Filbertine; Pattama Torvorapanit; Helen L Wright; Steven W Edwards; Asada Leelahavanichkul; Nattiya Hirankarn; Direkrit Chiewchengchol
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

3.  Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland.

Authors:  Hsin-Chieh Yeh; Jennifer L Kraschnewski; Lan Kong; Erik B Lehman; Emily S Heilbrunn; Pamela Williams; Jennifer M Poger; Erica Francis; Cindy L Bryce
Journal:  BMJ Open Diabetes Res Care       Date:  2022-06

Review 4.  Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.

Authors:  Rahnuma Ahmad; Mainul Haque
Journal:  Vaccines (Basel)       Date:  2022-04-14

5.  Neutrophil Extracellular Traps: New Aspects.

Authors:  N V Vorobjeva
Journal:  Moscow Univ Biol Sci Bull       Date:  2021-02-08

Review 6.  Neutrophils and Influenza: A Thin Line between Helpful and Harmful.

Authors:  Sneha T George; Jonathan Lai; Julia Ma; Hannah D Stacey; Matthew S Miller; Caitlin E Mullarkey
Journal:  Vaccines (Basel)       Date:  2021-06-04

Review 7.  Neutrophil subsets and their differential roles in viral respiratory diseases.

Authors:  Yuning Zhang; Quanbo Wang; Charles R Mackay; Lai Guan Ng; Immanuel Kwok
Journal:  J Leukoc Biol       Date:  2022-01-18       Impact factor: 6.011

Review 8.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.

Authors:  Claire S Whyte; Gael B Morrow; Joanne L Mitchell; Pratima Chowdary; Nicola J Mutch
Journal:  J Thromb Haemost       Date:  2020-06-03       Impact factor: 16.036

Review 9.  Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

Authors:  Frank M P van Haren; Clive Page; John G Laffey; Antonio Artigas; Marta Camprubi-Rimblas; Quentin Nunes; Roger Smith; Janis Shute; Mary Carroll; Julia Tree; Miles Carroll; Dave Singh; Tom Wilkinson; Barry Dixon
Journal:  Crit Care       Date:  2020-07-22       Impact factor: 9.097

10.  Vascular occlusion by neutrophil extracellular traps in COVID-19.

Authors:  Moritz Leppkes; Jasmin Knopf; Elisabeth Naschberger; Aylin Lindemann; Jeeshan Singh; Irmgard Herrmann; Michael Stürzl; Léonie Staats; Aparna Mahajan; Christine Schauer; Anita N Kremer; Simon Völkl; Kerstin Amann; Katja Evert; Christina Falkeis; Andreas Wehrfritz; Ralf J Rieker; Arndt Hartmann; Andreas E Kremer; Markus F Neurath; Luis E Muñoz; Georg Schett; Martin Herrmann
Journal:  EBioMedicine       Date:  2020-07-31       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.